Screening for autoimmune atrophic gastritis by serum gastrin measurement in subjects with type 1 diabetes
Authors' conclusion
In subjects with T1DM and PCA, serum gastrin is a reliable biomarker of gastric atrophy that can be used to select subjects requiring gastroduodenal fibroscopy.
Study context
- Population
- Subjects with T1D and parietal cell autoantibodies (PCA+), 2014–2018122 PCA+ screened
- Participants
- 1,425 subjects
- Comparison
- Serum gastrin vs histopathological gold standard for gastric atrophy
- Outcome
- Predictive value of serum gastrin for gastric atrophy vs histopathology
Methodological detailsretrospective, consecutive subjects
- Retrospective
- Consecutive subjects
Performance
As reported in the abstract
Prediction of gastric atrophy
| Test or model | Sensitivity | Specificity |
|---|---|---|
| Serum gastrin | 91 % | 82 % |
Serum gastrin
Sensitivity91 %
Specificity82 %
Further findings
Iron deficiency, gastric atrophy vs no atrophy
P < 0.0001
Vitamin B12 deficiency, gastric atrophy vs no atrophy
P < 0.0001
PCA positivity
- PCA+ among T1D subjects
- 185/1,425 (13 %)
- PCA positivity associated with female sex, older age, longer T1D duration, anti-GAD and anti-thyroperoxydase autoantibodies
Screening findings in PCA+ subjects
- Participated in screening
- 122 (66 %)
- Autoimmune atrophic gastritis (AAG)
- 69/122 (57 %)
- Helicobacter pylori infection
- 20/122 (16 %)
- Pre-tumoral lesion among AAG
- 44/69 (64 %)
- Tumor among AAG
- 6 %
Original publication
Screening for autoimmune atrophic gastritis by serum gastrin measurement in subjects with type 1 diabetes. Diabetes Metab. Published 18 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →